Methods for determining cost-benefit ratios for pharmaceuticals in Germany
- 21 June 2007
- journal article
- review article
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 8 (1) , 5-31
Abstract
The aim of this methodological paper is to summarize evidence on how to implement cost-benefit assessment according to the new German legislative framework (Competition Enhancement Act). Given the complexity of existing health policy frameworks within industrialised countries in adapting health economics in their respective regulatory scheme, no clear international scientific consensus on which health economic methods should be chosen for assessment can be determined. Nevertheless, a broad consensus on the internal properties of methods itself can be found. Based on these common international standards in methodology, this work provides a minimum catalogue of methods and criteria that meet legal and local German requirements with regard to specific factors of its health care system. Aside from categorising clearly defined standards (e.g., study forms, cost and benefit categories) the suggested catalogue specifies some intensively debated areas in Germany (e.g., the QALY, modelling, the perspective used in the assessment). After the proposition of certain methods the paper leads to a first recommendation of a detailed assessment-process itself specific for the German way in implementing cost-benefit ratios within regulatory decision making in Germany.Keywords
This publication has 56 references indexed in Scilit:
- Good Practice Guidelines for Decision-Analytic Modelling in Health Technology AssessmentPharmacoEconomics, 2006
- Probabilistic Analysis of Cost-Effectiveness Models: Statistical Representation of Parameter UncertaintyValue in Health, 2005
- The Friction-Cost MethodPharmacoEconomics, 2005
- A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between CountriesPharmacoEconomics, 2004
- The lag between effectiveness and cost-effectiveness evidence of new drugsThe European Journal of Health Economics, 2003
- Addressing uncertainty in medical cost–effectiveness analysisJournal of Health Economics, 2001
- Developing Guidance for Budget Impact AnalysisPharmacoEconomics, 2001
- Decision Analytic Modelling in the Economic Evaluation of Health TechnologiesPharmacoEconomics, 2000
- An Introduction to Markov Modelling for Economic EvaluationPharmacoEconomics, 1998
- The Decision Rules of Cost-Effectiveness AnalysisPharmacoEconomics, 1996